Newsfeeds Archive - Spark Newswire

1 minute read

After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans’ Health Information Stolen In Data Breach In February

May 24, 12:00 PM

Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications.

ABBV

4 minute read

Analyst Ratings

ACADIA Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (25 Ratings)

By Benzinga Insights

April 30, 11:01 AM

ACADIA Pharmaceuticals (NASDAQ:ACAD) has been analyzed by 25 analysts in the last three months, revealing a diverse range…

ACAD

2 minute read

Acadia Pharmaceuticals Presents New DAYBUE Clinical Data At The 2024 American Academy Of Neurology Annual Meeting

By Benzinga Newsdesk

April 17, 4:19 PM

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that two oral presentations featuring DAYBUE™ (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (AAN) 2024

ACAD

4 minute read

Analyst Ratings

Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals

By Benzinga Insights

April 10, 4:01 PM

26 analysts have expressed a variety of opinions on ACADIA Pharmaceuticals (NASDAQ:ACAD) over the past quarter, offering a…

ACAD

4 minute read

Analyst Ratings

Analyst Scoreboard: 12 Ratings For ACADIA Pharmaceuticals

By Benzinga Insights

January 24, 8:00 AM

ACADIA Pharmaceuticals (NASDAQ:ACAD) has been analyzed by 12 analysts in the last three months, revealing a diverse range…

ACAD

2 minute read

Expedia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Friday

By Avi Kapoor

December 29, 10:20 AM

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

ACAD

4 minute read

Analyst Ratings

Deep Dive Into ACADIA Pharmaceuticals Stock: Analyst Perspectives (13 Ratings)

By Benzinga Insights

December 29, 9:00 AM

Analysts’ ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) over the last quarter vary from bullish to bearish, as provided by…

ACAD

1 minute read

News

Acadia Pharmaceuticals Confirms Delaware District Court Issued A Claim Construction Order In Favor Of Acadia Regarding Its ‘721 Formulation Patent For NUPLAZID®

By Benzinga Newsdesk

December 14, 3:20 AM

- This is the second patent ruling issued today from the Court in favor of Acadia Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the U.S. District Court for the District of Delaware has issued a

ACAD

1 minute read

Movers
News

What’s Going On With Acadia Pharmaceuticals Stock?

By Erica Kollmann

December 13, 1:44 PM

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) shares are trading higher Wednesday after the company won summary judgement in a patent suit regarding its Nuplazid drug. What To Know:

ACAD